PMID- 35860593
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220722
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Daily Management of Patients on Multikinase Inhibitors' Treatment.
PG  - 903532
LID - 10.3389/fonc.2022.903532 [doi]
LID - 903532
AB  - In a minority of differentiated thyroid cancer (TC) cases and in a large 
      percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the 
      prognosis is poor due to the lack of response to conventional treatments. In the 
      last two decades, multikinase inhibitor (MKI) compounds have been developed and 
      demonstrated to be very effective in these aggressive cases. Besides the great 
      efficacy, several adverse events (AEs) have been reported in virtually all 
      patients treated with MKIs, largely overlapping between different compounds and 
      including hypertension, diarrhea, anorexia, decreased weight, fatigue, and 
      proteinuria. Most grade 3-4 adverse reactions occur during the first 6 months of 
      treatment and require dosage reduction and/or drug discontinuation. Due to 
      severity of the AEs related to the treatment with MKIs, a multidisciplinary team 
      is definitely required for the daily management of these patients, for the 
      evaluation of the disease status, and the psychophysical condition. Moreover, it 
      is crucial that the patients could have a facilitated access to reach either 
      specialist doctors or nurses who must have been trained to follow them for their 
      individual clinical complications. The follow-up visits should take place at 
      monthly intervals until the sixth month and then every 1-2 months until the 
      completion of the first year of treatment. The flow chart followed at our 
      tertiary center is reported in the present review as a real-life-based example 
      for the follow-up of patients with advanced TC on MKI treatment.
CI  - Copyright (c) 2022 Colombo, De Leo, Trevisan, Giancola, Scaltrito and Fugazzola.
FAU - Colombo, Carla
AU  - Colombo C
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan, 
      Italy.
FAU - De Leo, Simone
AU  - De Leo S
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
FAU - Trevisan, Matteo
AU  - Trevisan M
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
FAU - Giancola, Noemi
AU  - Giancola N
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
FAU - Scaltrito, Anna
AU  - Scaltrito A
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
FAU - Fugazzola, Laura
AU  - Fugazzola L
AD  - Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, 
      Italiano, Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220704
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9290676
OTO - NOTNLM
OT  - Cabozantinib
OT  - Lenvatinib
OT  - MKI
OT  - QoL
OT  - Vandetanib
OT  - multidisciplinary tumor board
OT  - prehabilitation
OT  - thyroid cancer
COIS- LF is a consultant for Eisai Europe Limited. The remaining authors declare that 
      the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/22 06:01
PMCR- 2022/01/01
CRDT- 2022/07/21 02:34
PHST- 2022/03/24 00:00 [received]
PHST- 2022/06/06 00:00 [accepted]
PHST- 2022/07/21 02:34 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/22 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.903532 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 4;12:903532. doi: 10.3389/fonc.2022.903532. eCollection 
      2022.